219 related articles for article (PubMed ID: 18829252)
1. [Prevention of chronic obstructive pulmonary disease exacerbations].
Dusser D
Presse Med; 2008 Nov; 37(11):1604-8. PubMed ID: 18829252
[TBL] [Abstract][Full Text] [Related]
2. Innovations to achieve excellence in COPD diagnosis and treatment in primary care.
Fromer L; Barnes T; Garvey C; Ortiz G; Saver DF; Yawn B
Postgrad Med; 2010 Sep; 122(5):150-64. PubMed ID: 20861599
[TBL] [Abstract][Full Text] [Related]
3. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
4. Common lung conditions: chronic obstructive pulmonary disease.
Delzell JE
FP Essent; 2013 Jun; 409():23-31. PubMed ID: 23767419
[TBL] [Abstract][Full Text] [Related]
5. Contemporary management of chronic obstructive pulmonary disease: scientific review.
Sin DD; McAlister FA; Man SF; Anthonisen NR
JAMA; 2003 Nov; 290(17):2301-12. PubMed ID: 14600189
[TBL] [Abstract][Full Text] [Related]
6. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
7. [Acute exacerbations of chronic obstructive pulmonary disease].
Chabot F; Gomez E; Guillaumot A; Kheir A; Chaouat A
Presse Med; 2009 Mar; 38(3):485-95. PubMed ID: 19185446
[TBL] [Abstract][Full Text] [Related]
8. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
[TBL] [Abstract][Full Text] [Related]
9. Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease.
Calverley PM
Proc Am Thorac Soc; 2004; 1(2):121-4. PubMed ID: 16113424
[TBL] [Abstract][Full Text] [Related]
10. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.
Rabe KF; Fabbri LM; Israel E; Kögler H; Riemann K; Schmidt H; Glaab T; Vogelmeier CF
Lancet Respir Med; 2014 Jan; 2(1):44-53. PubMed ID: 24461901
[TBL] [Abstract][Full Text] [Related]
11. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
12. Guideline for the management of chronic obstructive pulmonary disease--2011 update.
Abdool-Gaffar MS; Ambaram A; Ainslie GM; Bolliger CT; Feldman C; Geffen L; Irusen EM; Joubert J; Lalloo UG; Mabaso TT; Nyamande K; O'Brien J; Otto W; Raine R; Richards G; Smith C; Stickells D; Venter A; Visser S; Wong M;
S Afr Med J; 2011 Jan; 101(1 Pt 2):63-73. PubMed ID: 21526617
[TBL] [Abstract][Full Text] [Related]
13. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
Kardos P; Wencker M; Glaab T; Vogelmeier C
Am J Respir Crit Care Med; 2007 Jan; 175(2):144-9. PubMed ID: 17053207
[TBL] [Abstract][Full Text] [Related]
14. [The influence of treatment with formoterol, formoterol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and simple, morning everyday activities in patients with chronic obstructive pulmonary disease (COPD)].
Szmidt M
Pneumonol Alergol Pol; 2012; 80(3):255-62. PubMed ID: 22562275
[TBL] [Abstract][Full Text] [Related]
15. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease.
Niewoehner DE
Am J Med; 2006 Oct; 119(10 Suppl 1):38-45. PubMed ID: 16996898
[TBL] [Abstract][Full Text] [Related]
16. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
17. [Chronic obstructive pulmonary disease exacerbations and their impact on the long-term natural history of the disease].
Dusser D
Presse Med; 2008 Nov; 37(11):1599-603. PubMed ID: 18823740
[TBL] [Abstract][Full Text] [Related]
18. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
[TBL] [Abstract][Full Text] [Related]
19. [Long-term treatment strategy in chronic obstructive pulmonary disease: how to change the course of the disease].
Devillier P; Salvator H; Roche N; Grassin-Delyle S; Naline E; Dorocant S; Neveu H
Presse Med; 2014 Dec; 43(12 Pt 1):1368-80. PubMed ID: 25455634
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of tiotropium in the prevention of exacerbations of COPD.
Anzueto A; Miravitlles M
Ther Adv Respir Dis; 2009 Jun; 3(3):103-11. PubMed ID: 19617284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
